This website is intended for healthcare professionals only and contains promotional content.

Report an adverse event here
Link Logo
United Kingdom - English

United Kingdom - English

United Kingdom | English

These country specific websites are specifically intended for healthcare professionals in listed countries only.

Europe

Deutschland - DeutschDeutschland - Deutsch España - EspañolEspaña - Español Italia - ItalianoItalia - Italiano United Kingdom - EnglishUnited Kingdom - English

NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.​

Abstral-product-image

Abstral®

fentanyl citrate

Abstral® is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.*1

Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

Click here for Prescribing Information.

Time Matters

Abstral® is a sublingual tablet designed to dissolve upon contact with the sublingual mucosal membrane, allowing fentanyl to be rapidly absorbed into the bloodstream.1

It has been shown to deliver measurable relief from as early as 10 minutes2 and to improve quality of life,3 allowing your patients to make the most of their precious time with family and loved ones.

Treating breakthrough cancer pain with Abstral®

*Abstral® should only be administered to patients who are considered tolerant to their opioid therapy for persistent cancer pain. Patients can be considered opioid tolerant if they take at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.1

Contents

Abstral® (fentanyl (as citrate)) is indicated for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain. Please note not all medicines containing opioids are authorised for all types of pain indication. Refer to the summary of product characteristics before prescribing. For advice on the responsible use of opioids, including those indicated for other types of pain, please click here

Average:

  • References

    1. Abstral® Summary of Product Characteristics.

    2. Rauck RL et al. Curr Med Res Opin. 2009;25(12):2877-2885.

    3. Überall MA, et al. Curr Med Res Opin. 2011;27(7):1385-1394.

    KKI/INT/ABS/0009 November 2023